Diaceutics are finalists in four categories at the Health Tech Awards 2021 organised by Health Tech Newspaper (HTN). The categories include Best Use of Data, Best Use of AI & Automation, Innovation in Digital Pathways and Excellence in Cloud Technologies.
In the Best Use of Data category, eight finalists highlight how data is driving improved decision making and intelligence with a further eight finalists showcasing how they’ve made Best Use of AI and Automation Tools. The Innovation in Digital Pathways’ category features ten finalists highlighting health tech innovations and providers who are making an impact with four finalists in the running for the Excellence in Cloud Technologies award.
The HTN Awards help to share and celebrate digital teams, programmes, innovations, and health tech suppliers that have made a difference through the year. This year’s ceremony will be a digital awards evening that takes place on October 7, 2021.
Diaceutics’ entries focus on the application of machine learning and AI to identify the best possible testing journey for patients using DDPs® (Diagnostic Deductive Pathways). Enabled by DXRX – The Diagnostic Network® which is the world’s first diagnostic commercialization platform for Precision Medicine, Diaceutics integrates multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
By combining data from multiple sources including laboratory result data, diagnostic profiling meta data and CMS and commercial claims data into its DXRX platform, Diaceutics are able to provide access to 365m+ de-identified patient records globally in 53 countries. Through machine learning and the standardisation of millions of aggregated de-identified patient testing events, Diaceutics can identify the best possible testing journey or “Deductive Diagnostic Pathway (DDP®)” for patients at disease level, providing the industry with a guide to ‘getting the right medicines to the right patients, faster’.
With 476 potential Precision Medicine therapies now in late phase of development and over 30 per cent of all FDA approvals between 2018-2020 being for Precision Medicines, the pipeline of therapies requiring a companion diagnostic solution is rapidly growing. Diaceutics has embarked on addressing this significant and pressing issue by building its data enabled platform, which has been designed to get ‘every patient the right treatment at the right time’ by identifying and solving hurdles in a therapy’s testing ecosystem ahead of therapy launch.
To date, Diaceutics has leveraged deep disease level data analytics and implementation solutions to improve the diagnostic testing infrastructure for over 600 projects with 39 of the world’s leading pharmaceutical companies.
By labelling clinical data, it allows data-driven insights, providing a cleaner and easier dataset for Diaceutics to work with, as well as allowing the creation of groupings and filters. By using a standardised six-step approach for better data, testing and treatment, it ensures that anyone working with the data has the same starting point with same patient cohort and methods. This means data can be analysed and aggregated at a high level quickly and efficiently, meaning ‘more patients get the right treatment at the right time enabled by DXRX’.
